BlossomHill director reports option, 578K-share interest
BlossomHill Therapeutics, Inc. (BLSM) reports the initial beneficial ownership of director Sundeep Agrawal.
Rhea-AI Filing Summary
BlossomHill Therapeutics, Inc. (BLSM) reports the initial beneficial ownership of director Sundeep Agrawal. He holds a Director Stock Option covering 10,671 shares of common stock at an exercise price of $6.28 per share, expiring on August 15, 2035, vesting in 12 equal monthly installments beginning on August 15, 2025. He is also reported as having indirect ownership of 578,524 underlying common shares through Series B Preferred Stock held by Brahma BlossomHill Partners, LLC, which is convertible into common stock on a 1-for-1 basis upon the closing of the company’s initial public offering, with no expiration date; Agrawal disclaims beneficial ownership of these indirect securities.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Agrawal Sundeep
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Director Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Series B Preferred Stock F2, F3 | -- | -- | -- |
Holdings After Transaction:
Director Stock Option (Right to Buy) — 10,671 contracts (Direct);
Series B Preferred Stock — 578,524 contracts (Indirect, By Brahma BlossomHill Partners, LLC)
Footnotes (3)
- F1. The shares vest in 12 equal monthly installments beginning on August 15, 2025.
- F2. Each share of Series B Preferred Stock is convertible into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Series B Preferred Stock has no expiration date.
- F3. The securities are held of record by Brahma BlossomHill Partners, LLC ("Brahma Partners"). The Reporting Person is the founder and managing partner of Brahma Capital, LLC, which manages Brahma Partners, and may be deemed to have sole voting and/or investment power over the securities held by Brahma Partners. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Key Figures
Director Stock Option underlying shares: 10,671 shares
Director Stock Option exercise price: $6.28 per share
Director Stock Option expiration: August 15, 2035
+3 more
6 metrics
Director Stock Option underlying shares
10,671 shares
Common Stock underlying Director Stock Option held by Sundeep Agrawal
Director Stock Option exercise price
$6.28 per share
Exercise price for Director Stock Option over BlossomHill common stock
Director Stock Option expiration
August 15, 2035
Expiration date of Director Stock Option
Option vesting schedule
12 monthly installments
Option vests in 12 equal monthly installments beginning on August 15, 2025
Series B Preferred underlying shares
578,524 shares
Underlying BlossomHill common shares for Series B Preferred Stock held indirectly
Conversion ratio
1 share common per 1 share Series B Preferred
Each share of Series B Preferred Stock converts into 1 share of Common Stock upon IPO closing
Key Terms
Director Stock Option (Right to Buy), Series B Preferred Stock, convertible, beneficial ownership
4 terms
Director Stock Option (Right to Buy) financial
"security_title: Director Stock Option (Right to Buy)"
Series B Preferred Stock financial
"security_title: Series B Preferred Stock"
Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.
convertible financial
"Each share of Series B Preferred Stock is convertible into 1 share"
A convertible is a type of investment that starts as a loan or preferred stake (like a bond or preferred share) but can be exchanged for common shares of the company at a set price or under certain conditions. It matters to investors because it offers a mix of steady income and downside protection like a loan, plus the upside of stock ownership if the company does well—similar to holding a coupon that you can trade for a full ticket if the event becomes valuable.
beneficial ownership financial
"The Reporting Person disclaims beneficial ownership of these securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
What insider holdings did director Sundeep Agrawal report in Form 3 for BLSM?
Director Sundeep Agrawal reported a stock option for 10,671 BLSM common shares at $6.28 per share, expiring August 15, 2035, plus indirect interest in 578,524 underlying common shares via Series B Preferred Stock held by Brahma BlossomHill Partners, LLC.
What are the key terms of Sundeep Agrawal’s stock option in BlossomHill Therapeutics (BLSM)?
Agrawal holds a Director Stock Option over 10,671 BLSM common shares with an exercise price of $6.28 and expiration on August 15, 2035. The option vests in 12 equal monthly installments starting August 15, 2025.
Is the Series B Preferred Stock in BLSM held directly by Sundeep Agrawal?
No. The Series B Preferred Stock is held of record by Brahma BlossomHill Partners, LLC. Agrawal is associated through Brahma Capital, LLC and may be deemed to have voting and/or investment power but expressly disclaims beneficial ownership of these securities.
Does this BLSM Form 3 report any insider purchases or sales by Sundeep Agrawal?
The Form 3 presents holdings only, not purchases or sales. It lists a vested-and-vesting stock option and indirectly held Series B Preferred Stock. The transaction summary shows no buy or sell transactions, only current derivative and preferred positions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
